3. Selected Balance Sheet Components

Accrued expenses and other current liabilities

At December 31, 2017 and 2016, accrued expenses and other current liabilities were comprised of the following (in thousands):

	2017		2016
Accrued bonuses and payroll related expenses	$	636	$	549
Other accrued expenses		406		248
Accrued expenses and other current liabilities	$	1,042	$	797

Intangible assets, net

In 2011, OncoCyte, through its then parent, BioTime, acquired substantially all of the assets of Cell Targeting, Inc., a company that was engaged in cancer therapy. The assets acquired consist primarily of patents, patent applications, and licenses to use certain patents. OncoCyte amortizes intangible assets over their useful lives estimated to be 10 years at the date of the acquisition.

At December 31, 2017 and 2016, intangible assets were comprised of the following (in thousands):

	2017			2016
Intangible assets	$	2,419		$	2,419
Accumulated amortization		(1,673	)		(1,431	)
Intangible assets, net	$	746		$	988

Amortization expense amounted to approximately $242,000 annually.

Equipment and furniture, net

At December 31, 2017 and 2016, equipment and furniture were comprised of the following (in thousands):

	2017			2016
Equipment and furniture	$	1,479		$	1,007
Accumulated depreciation		(657	)		(319	)
Equipment and furniture, net	$	822		$	688

Depreciation expense amounted to approximately $338,000, $145,000 and $41,000 for the years ended December 31, 2017, 2016 and 2015, respectively. During the year ended December 31, 2017 and 2016, OncoCyte entered into capital leases for laboratory equipment totaling $381,000 and $626,000, respectively (see Note 9).